FIELD: medicine.
SUBSTANCE: what is presented is a group of inventions which refers to medicine, namely oncology. The group of inventions involves a recovered PDGFRcc-specific human antibody or an antibody fragment, a recovered polynucleotide, an expression vector, a recombinant cell, an antibody or an antibody fragment produced by recombinant cell culture, and also the use of these antibodies or their fragments for tumour growth inhibition in leiomyosarcoma and glioblastoma.
EFFECT: invention enables successful treatment of leiomyosarcoma and glioblastoma ensured by the use of the antibodies or their fragments which bind with human PDGFRoc and neutralise activation of the receptors involved in tumour angiogenesis growth.
10 cl, 20 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PDGFRα ANTIBODIES FOR TREATING SECONDARY BONE TUMOUR | 2006 |
|
RU2502523C2 |
| HUMAN ANTIBODIES TO RECEPTOR OF EPIDERMAL GROWTH FACTOR | 2005 |
|
RU2402569C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| METHOD FOR RECEPTOR TYROSINE KINASE INHIBITION WITH USE EXTRACELLULAR ANTAGONIST AND INTRACELLULAR ANTAGONIST | 2004 |
|
RU2431500C2 |
| RECEPTOR IGF-I ANTIBODIES | 2003 |
|
RU2421465C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| DETECTION OF CHEMOTHERAPY RESPONDERS | 2006 |
|
RU2416096C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| ANTIBODIES AGAINST AXL AND THEIR APPLICATION | 2011 |
|
RU2577986C2 |
| SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES | 2008 |
|
RU2519647C2 |
